eFFECTOR Therapeutics, Inc. (EFTR)
(Delayed Data from OTC)
$0.05 USD
0.00 (8.82%)
Updated Jul 25, 2024 09:37 AM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
EFTR 0.05 0.00(8.82%)
Will EFTR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for EFTR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EFTR
eFFECTOR Therapeutics (EFTR) Plunges 82% as NSCLC Study Fails
Does eFFECTOR Therapeutics, Inc. (EFTR) Have the Potential to Rally 814.53% as Wall Street Analysts Expect?
EFTR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nasdaq ETF's First Six-week Rally Since Jan 2020: Stock Winners
Biogen (BIIB), Eisai Seek Full Nod for Alzheimer Drug Leqembi
Reata (RETA) Stock Jumps as FDA Approves Rare Disease Drug
Other News for EFTR
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Dow Jumps 300 Points; Alimera Sciences Shares Spike Higher
eFFECTOR Therapeutics Initiates Wind-Down and Leadership Change
Twelve option delistings on June 24th
eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq